Showing 1–25 of 51 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Azar Najafi, Nahid Mahdian, Bahman Yousefi, Mohsen Karbalaei, Ali Kermanjani, et al.
…d in vivo examinations, such as recombinant BCG (rBCG), DNA vaccines, and subunit vaccines. Factors, such as applicability of vaccine candidates in all individuals, cost-effectiveness, long-term immunity and stimulation of a wide range of responses are important factors. Now, mos…
Yue Wang, Weibing Wang
…, treatments, and innovative tools such as new tuberculosis vaccines are urgently needed. Although there have been rapid advances in tuberculosis vaccine clinical research over the past decade, mathematical modelling studies, which can provide a method to predict the potential fu…
Eskild Petersen, David S.C. Hui, Jean B. Nachega, Francine Ntoumi, Delia Goletti, et al.
… for increasing access to affordable drugs, diagnostics and vaccines for other epidemic diseases affecting resource-poor countries. In April, 2021, a Brazil judge suspended drug patent extensions, a preliminary decision that could lower costs for drugs critical to treating COVID-…
Anne Margarita Dyrhol-Riise, PhD
…itors (COX-2i) can improve the immune system and strengthen vaccines responses. Hypothesis 1. A hyperactive COX-2/PGE2 signal system in active TB causes down-regulated immune responses that favour TB survival, but this can be abrogated by COX-2i. 2. TB-specific immunisation wit…
Naomi E. Aronson, MD, Merlin L. Robb, MD
The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high or moderate burden of TB. BCG will be compared with a pla…
Divya Goswami, Gautam Kalwadia, Kunal Saini, Anita Sondhi
… of TB, necessitating the importance of better and improved vaccines. The emergence of drug-resistant TB, like MDR-TB (multidrug-resistant TB and XDR-TB (extensively drug-resistant TB, has made the situation even more serious. Nearly nineteen new TB vaccines are in clinical trial…
Shantong Liu, Qianqian Zhang, Siqi Lin, Qiaoyu Yang, Jiang Pi, et al.
…the urgent need for novel treatment strategies. Therapeutic vaccines, an innovative immunotherapeutic approach, are designed to be administered alongside standard pharmacological treatments. By enhancing pathogen-specific immune responses in the host, these vaccines aim to eradic…
Nadia A. Sam‐Agudu, Chandy C. John
…e Tracker TeamCOVID-19 vaccine tracker.https://covid19.trackvaccines.org/Date: 2022Google Scholar Furthermore, while COVID-19 vaccine coverage in the United States is >20% for 5–11 year olds and approaching 60% for 12–17 year olds,4US Centers for Disease Control and PreventionCOV…
Elwira Sieniawska
…n a reduction in funding for tuberculosis treatment and BCG vaccines in children. The COVID-19 pandemic outbreak in 2020 disrupted essential health services and placed an additional burden on people with tuberculosis (World Health Organization, Global Tuberculosis Report, 2021). …
Eskild Petersen, Martin Rao, Giuseppe Ippolito, Gina Gualano, Jeremiah Chakaya, et al.
… and to conduct research on new diagnostics, treatments and vaccines required to achieve global TB control (Tiberi et al., 2018Tiberi S. Petersen E. Maeurer M. Ntoumi F. Yeboa-Manu D. Mwaba P. et al.Taking forward the Stop TB Partnership and World Health Organization Joint Theme …
David S.C. Hui, Chi Chiu Leung
…el TB vaccine candidates being developed include whole-cell vaccines, adjuvanted protein vaccines, viral vaccines, vaccines, are as a in diseases they are more on a population Unlike the protective effects of will not be by after the However, with the high global burden of latent…
Ambuj Kumar Kushwaha, Abhisheka Bansal, Gunjan Arora, Divya Kushwaha
…echanisms of action, identify new drug targets, and enhance vaccines and diagnostic tools (Basore et al., 2015; Kushwaha et al., 2018; Matteucci et al., 2022). This Frontiers in Cellular and Infection Microbiology Research Topic, "Mechanisms Driving Drug Resistance in Tuberculosi…
Cynthia Bin Eng Chee, David S.C. Hui
… continue to be important. The availability of pneumococcal vaccines and multiplex polymerase chain reactions (PCR) has led to a decreasing incidence of pneumococcal pneumonia and detection of more viral aetiologies in CAP. In recent years, rapid and automated molecular tests bas…
Ahmed Al Hammadi, Fatima Ali Salem Khalfan Al Dhaheri, Huda Sulaiman Al Dhanhani, Jens Thomsen
…on had been vaccinated with at least one dose of a COVID-19 vaccines, resulting in a mortality rate of only 0.24%, making it one of the lowest in the world.
Stefan H. E. Kaufmann
…ails to protect against pulmonary TB in all age groups. New vaccines against TB are urgently needed. New candidates that have entered clinical trials are killed whole cell vaccines, recombinant live vaccines, Mtb antigen-adjuvant formulations or viral vectors expressing Mtb antig…
Taru S. Dutt, Burton Karger, Amy Fox, Nathan Youssef, Rhythm Dadhwal, et al.
… because of the inadequacy of currently available drugs and vaccines. The most common clinical manifestation is pulmonary TB, and the Bacille Calmette Guerin (BCG) is the only licensed vaccine for protection against TB; however, its efficacy is highly variable. Today at least 52 …
SushantSatish Mane
… has led to intense research in this field. VPM1002 and MIP vaccines are in their Phase 3 trials to evaluate efficacy and safety for preventing TB disease in healthy household contacts >6 years, of newly diagnosed sputum-positive PTB patients.[8] VPM1002 is being evaluated additi…
Christoph Lange, Anca Vasiliù, Anna M. Mandalakas
Tuberculosis is the leading cause of death attributed to a single infectious pathogen worldwide. Despite the availability of anti-tuberculosis therapies for more than half a century, the number of people affected by tuberculosis reached a historical peak in 2021.1WHOGlobal tuberc…
Saima Abid
Antimicrobial resistance (AMR) is a growing public health threat. Resistant microorganisms (i.e. bacteria, viruses and some parasites) through genetic mutations become too strong that they become resistant to the antimicrobials (i.e. antibiotics, antivirals and antimalarial) over…
Christoph Lange, MD, PhD
It is a single-center, observational, prospective cohort study recruiting patients hospitalized at the multidrug-resistant tuberculosis ward at Marius Nasta Institute. This project aims to improve the individual patient management and TB treatment outcomes, especially for patient…
В. Н. Даниленко
…cluding virulence inhibitors; third, genetically engineered vaccines, the development of which will account for the existing negative international experience and new scientific approaches, including those proposed in Russia; and, fourth, a new class of adjuvants for vaccines bas…
Ameya D. Bendre, Pooja Singh, Swati Jaiswal
…athogenesis, developing new drugs and treatments, advancing vaccines and diagnostics, exploring innovative approaches for multidrug- and extensively drug-resistant TB, and investigating the molecular and genetic factors that influence mycobacterial responses to therapy, all to im…
Christoph Lange, Keertan Dheda, Dumitru Chesov, Anna M. Mandalakas, Zarir Udwadia, et al.
It is obvious that more efforts are needed, both in research and development and in implementation, to reduce the drug-resistant tuberculosis epidemic.1Lange C Dheda K Chesov D Mandalakas AM Udwadia Z Horsburgh Jr, CR Management of drug-resistant tuberculosis.Lancet. 2019; 394: 9…
Tasmin Nazim
…happening after covid‐19 we must work on drug discovery and vaccines to prevent TB from spreading. Objective This work is done on mycobacterium tuberculosis, the causative agent of tuberculosis, using laboratory experiments and computational biological tools to characterize methy…
Ke Hao, Lihong Fan
…sistant tuberculosis. Host-targeted therapy and therapeutic vaccines are new directions for research into TB adjuvant therapy.